Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Kidney Outcomes With SGLT-2 Inhibitors

Kidney Outcomes With SGLT-2 Inhibitors Kidney Outcomes With SGLT-2 Inhibitors LOURDES V. CROSS, PHARMD, BCACP, CDCES GREGORY HEATON, PHARMD Chronic kidney disease (CKD) is a progressive established renal disease if estimated glomerular disease that can cause numerous complications, filtration rate (eGFR) is adequate. The purpose of including electrolyte imbalances, anemia, and this article is to review the evidence supporting bone and mineral disorders. It may eventually the use of SGLT-2 inhibitors to preserve kidney progress to end-stage kidney disease (ESKD) function in people with diabetes (for SGLT-2 requiring dialysis and kidney transplant. Diabetes inhibitors renal dosing recommendations, see is a risk factor for CKD, which develops in 20% to Table 1). 40% of individuals with diabetes. Additionally, Pathophysiology and SGLT-2 Inhibitor the presence of CKD increases the risk of Mechanism cardiovascular disease. The development of diabetes-related kidney The American Diabetes Association (ADA) disease involves multiple changes, including recommends metformin as fi rst-line therapy glomerulopathy, progressive albuminuria, and for all patients with type 2 diabetes mellitus tubulointerstitial damage. Excessive levels of (T2D), including those with CKD. Metformin plasma glucose and amino acids in people with should be continued as long as it is tolerated diabetes has been linked to kidney infl ammation and not contraindicated. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ADCES in Practice SAGE

Kidney Outcomes With SGLT-2 Inhibitors

ADCES in Practice , Volume 9 (3): 4 – May 1, 2021

Loading next page...
 
/lp/sage/kidney-outcomes-with-sglt-2-inhibitors-TDUKH7xJek
Publisher
SAGE
Copyright
© 2021 by the American Association of Diabetes Educators
ISSN
2633-559X
eISSN
2633-5603
DOI
10.1177/2633559x211007065
Publisher site
See Article on Publisher Site

Abstract

Kidney Outcomes With SGLT-2 Inhibitors LOURDES V. CROSS, PHARMD, BCACP, CDCES GREGORY HEATON, PHARMD Chronic kidney disease (CKD) is a progressive established renal disease if estimated glomerular disease that can cause numerous complications, filtration rate (eGFR) is adequate. The purpose of including electrolyte imbalances, anemia, and this article is to review the evidence supporting bone and mineral disorders. It may eventually the use of SGLT-2 inhibitors to preserve kidney progress to end-stage kidney disease (ESKD) function in people with diabetes (for SGLT-2 requiring dialysis and kidney transplant. Diabetes inhibitors renal dosing recommendations, see is a risk factor for CKD, which develops in 20% to Table 1). 40% of individuals with diabetes. Additionally, Pathophysiology and SGLT-2 Inhibitor the presence of CKD increases the risk of Mechanism cardiovascular disease. The development of diabetes-related kidney The American Diabetes Association (ADA) disease involves multiple changes, including recommends metformin as fi rst-line therapy glomerulopathy, progressive albuminuria, and for all patients with type 2 diabetes mellitus tubulointerstitial damage. Excessive levels of (T2D), including those with CKD. Metformin plasma glucose and amino acids in people with should be continued as long as it is tolerated diabetes has been linked to kidney infl ammation and not contraindicated.

Journal

ADCES in PracticeSAGE

Published: May 1, 2021

There are no references for this article.